Varenicline for Smoking Cessation
Initiate varenicline with a standard titration schedule starting 1-2 weeks before the quit date: 0.5 mg once daily for days 1-3, then 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily for 12 weeks. 1, 2
Standard Dosing Schedule
The FDA-approved dosing regimen follows a structured titration approach 2:
- Days 1-3: 0.5 mg orally once daily
- Days 4-7: 0.5 mg orally twice daily
- Week 2 through Week 12: 1 mg orally twice daily (if tolerated)
Timing: Begin dosing 1-2 weeks before the target quit date. Alternatively, patients can start varenicline and then quit smoking between days 8-35 of treatment 1, 2.
Duration: A minimum of 12 weeks is recommended for the initial quit attempt. For patients who successfully quit, an additional 12-week course (total 24 weeks) is recommended to increase long-term abstinence rates 1.
Administration: Take orally after eating with a full glass of water 2.
Renal Dose Adjustments
Renal function is the most clinically important factor affecting varenicline exposure 3:
- Mild to moderate renal impairment: No dose adjustment necessary 2
- Severe renal impairment (CrCl <30 mL/min): Start with 0.5 mg once daily, then titrate to 0.5 mg twice daily as tolerated 1, 2
- End-stage renal disease on hemodialysis: Maximum dose of 0.5 mg once daily if tolerated 1, 2
No hepatic dose adjustment is required 2.
Contraindications
Absolute contraindication: History of serious hypersensitivity or skin reactions to varenicline 2.
Special population contraindication: Patients with brain metastases due to seizure risk 1. This is particularly relevant in oncology settings where varenicline is otherwise a preferred first-line agent.
Critical Counseling Points
Neuropsychiatric Monitoring
Monitor closely for neuropsychiatric adverse events, though recent high-quality evidence shows these are uncommon. The EAGLES trial (n=8,058) demonstrated that neuropsychiatric adverse events with varenicline were not significantly increased compared to nicotine patches or placebo, even in patients with psychiatric disorders 1.
However, postmarketing reports have documented serious events including 2:
- Changes in mood (depression, mania)
- Psychosis, hallucinations, paranoia, delusions
- Suicidal ideation, suicide attempts
- Aggression, hostility, agitation, anxiety
Action required: Instruct patients to discontinue varenicline immediately and contact their healthcare provider if these symptoms develop 2.
Common Side Effects
Nausea is the most common adverse effect (16-42% in clinical trials) 4:
- Dose-dependent and more common in females 3
- More frequent with non-titrated dosing schedules 4
- May require management, especially in cancer patients receiving chemotherapy 1
- Rarely leads to discontinuation 4
Management strategy: Consider dose reduction (temporary or permanent) if adverse effects are intolerable 2. Lower doses (average 1.3 mg/day) can eliminate many adverse effects while retaining efficacy 5.
Other Important Warnings
Seizures: New or worsening seizures have been observed. Use cautiously in patients with seizure history or risk factors 2.
Alcohol interaction: Increased effects of alcohol reported. Advise patients to reduce alcohol consumption until they know how varenicline affects them 2.
Accidental injury: Monitor for potential impairment that could affect activities requiring alertness 2.
Behavioral Support Integration
Varenicline must be combined with behavioral counseling for optimal outcomes 1, 6. The combination is superior to either approach alone:
- Minimum of 4 counseling sessions over 12 weeks preferred 1
- First follow-up within 2-3 weeks of starting medication 1
- Can coordinate with routine oncology appointments to minimize burden 1
- Refer to quitlines (e.g., This is Quitting) as adjunct support 7
Gradual Quit Approach Option
For patients unable or unwilling to quit abruptly 2:
- Start varenicline and reduce smoking by 50% within first 4 weeks
- Reduce by additional 50% in next 4 weeks
- Achieve complete abstinence by week 12
- Continue treatment for additional 12 weeks (total 24 weeks)
Managing Treatment Failure
If patients fail to quit or relapse 1:
- Identify and address contributing factors
- Consider continuing/resuming varenicline
- May extend therapy to 6-12 months
- Intensify behavioral therapy with specialist referral if needed
Common pitfall: Discontinuing varenicline too early. Nicotine withdrawal symptoms peak within 1-2 weeks; encourage continued therapy through brief slips as patients may quit later once withdrawal subsides 1.
Follow-up Schedule
- Week 2-3: First assessment of smoking status and medication tolerability 1
- Week 12: End of initial treatment phase assessment
- Ongoing: Minimum 12-week intervals during extended therapy 1
- Post-treatment: Continue monitoring for relapse risk 1
Special Populations
Elderly patients: No dose adjustment based on age alone, but monitor renal function as elderly patients are more likely to have decreased kidney function 2, 8.
Pregnancy: Not specifically addressed in provided evidence; consult current FDA labeling.
Youth/adolescents: Recent evidence (2025) shows efficacy in ages 16-25 for nicotine vaping cessation, though not currently FDA-approved for under 18 7.